Combined oral contraceptive use and epithelial ovarian cancer risk: Time-related effects

Epidemiology

Volumn 19, Issue 2, 2008, Pages 237-243

  Lurie, Galina ^a   Wilkens, Lynne R ^a   Thompson, Pamela J ^a   McDuffie, Katharine E ^a   Carney, Michael E ^b   Terada, Keith Y ^b   Goodman, Marc T ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; OVARY CANCER; PRIORITY JOURNAL; RISK REDUCTION;

ADULT; AGE FACTORS; AGED; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); CONTRACEPTIVES, ORAL, COMBINED; EPITHELIUM; FEMALE; HAWAII; HUMANS; LOGISTIC MODELS; LOS ANGELES; MATERNAL AGE; MIDDLE AGED; OVARIAN NEOPLASMS; REGISTRIES; RISK FACTORS; TIME FACTORS;

EID: 39149104946     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e31816334c5     Document Type: Article

References (29)

1. La Vecchia C. Oral contraceptives and ovarian cancer: an update, 1998-2004. Eur J Cancer Prev. 2006;15:117-124.
2. Hankinson SE, Colditz GA, Hunter DJ, et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol. 1992;80:708-714.
3. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer. 2001;95:370-374.
4. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol. 2000;152:233-241.
5. Riman T, Dickman PW, Nilsson S, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol. 2002;156:363-373.
6. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136:1212-1220.
7. Schildkraut JM, Calingaert B, Marchbanks PA, et al. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst. 2002;94:32-38.
8. Pike MC, Pearce CL, Peters R, et al. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril. 2004;82:186-195.
9. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med. 1987;316:650-655.
10. Greer JB, Modugno F, Allen GO, et al. Short-term oral contraceptive use and the risk of epithelial ovarian cancer. Am J Epidemiol. 2005;162:66-72.
11. Gross TP, Schlesselman JJ, Stadel BV, et al. The risk of epithelial ovarian cancer in short-term users of oral contraceptives. Am J Epidemiol. 1992;136:46-53.
12. Tung KH, Goodman MT, Wu AH, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol. 2003;158:629-638.
13. Bosetti C, Negri E, Trichopoulos D, et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer. 2002;102:262-265.
14. Kumle M, Weiderpass E, Braaten T, et al. Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Br J Cancer. 2004;90:1386-1391.
15. Siskind V, Green A, Bain C, et al. Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology. 2000;11:106-110.
16. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet. 1994;344:1250-1254.
17. Pike MC, Spicer DV. Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer. 2000;7:73-83.
18. Lurie G, Thompson P, McDuffie KE, et al. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol. 2007;109:597-607.
19. Oyama N, Johnson DB. Hawaii Health Surveillance Program Survey Methods and Procedures. R & S Report No 54. Honolulu, Hawaii: State Department of Health Research; 1986.
20. Waksberg J. Sampling methods for random digit dialing. J Am Stat Assoc. 1976;73:40-46.
21. Rothman KJ, Greenland S, eds. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1998.
22. Bolt HM, Bolt WH. Pharmacokinetics of mestranol in man in relation to its oestrogenic activity. Eur J Clin Pharmacol. 1974;7:295-305.
23. Dickey RP, Stone SC. Progestational potency of oral contraceptives. Obstet Gynecol. 1976;47:106-112.
24. Dickey RP. Managing Contraceptive Pill Patients. 8th ed. Durant, OK: Essential Medical Information Systems, Inc.; 1994.
25. Fathalla MF. Factors in the causation and incidence of ovarian cancer. Obstet Gynecol Surv. 1972;27:751-768.
26. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998;90:1774-1786.
27. Panzer C, Wise S, Fantini G, et al. Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction. J Sex Med. 2006;3:104-113.
28. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71:717-721.
29. Ho SM. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol. 2003;1:73.